Researcher Profile

Researcher Profile

David Claxton, MD

David Claxton, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Immunotherapy
Leukemia and Lymphoma
dfc10@psu.edu

Research Interests

Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

  • Acute Myeloid Leukemia
  • Therapeutics
  • Leukemia
  • Neoplasms
  • Genes
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Bone Marrow
  • Transplants
  • Drug Therapy
  • T-Lymphocytes
  • Proteins
  • Stem Cells

Clinical Trials

Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Biologic Studies of Experimental Anti-Cancer Therapeutics in Human Leukemia Cells
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications

2021

Jia, B, Zhao, C, Bayerl, M, Shike, H, Claxton, DF, Ehmann, WC, Mineishi, S, Schell, TD, Zheng, P, Zhang, Y, Shultz, LD, Prabhu, KS, Paulson, RF & Zheng, H 2021, 'A novel clinically relevant graft-versus-leukemia model in humanized mice', Journal of Leukocyte Biology. https://doi.org/10.1002/JLB.5AB0820-542RR
Advani, AS, Larsen, E, Laumann, K, Luger, SM, Liedtke, M, Devidas, M, Chen, Z, Yin, J, Foster, MC, Claxton, D, Coffan, K, Tallman, MS, Appelbaum, FR, Erba, H, Stone, RM, Hunger, SP, McNeer, JL, Loh, ML, Raetz, E, Winick, N, Carroll, W, Larson, RA & Stock, W 2021, 'Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia', Blood Advances, vol. 5, no. 2, pp. 504-512. https://doi.org/10.1182/bloodadvances.2020002439
Zhu, G, Luo, H, Feng, Y, Guryanova, OA, Xu, J, Chen, S, Lai, Q, Sharma, A, Xu, B, Zhao, Z, Feng, R, Ni, H, Claxton, D, Guo, Y, Mesa, RA, Qiu, Y, Yang, FC, Li, W, Nimer, SD, Huang, S & Xu, M 2021, 'HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia', Nature communications, vol. 12, no. 1, 1956. https://doi.org/10.1038/s41467-021-22095-2
List, AF, Sun, Z, Verma, A, Bennett, JM, Komrokji, RS, McGraw, K, Maciejewski, J, Altman, JK, Cheema, PS, Claxton, DF, Luger, SM, Mattison, RJ, Wassenaar, TR, Artz, AS, Schiffer, CA, Litzow, MR & Tallman, MS 2021, 'Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 9, pp. 1001-1009. https://doi.org/10.1200/JCO.20.01691
Klink, M, Rahman, MA, Song, C, Dhanyamraju, PK, Ehudin, M, Ding, Y, Steffens, S, Bhadauria, P, Iyer, S, Aliaga, C, Desai, D, Huang, S, Claxton, D, Sharma, A & Gowda, C 2021, 'Mechanistic basis for in vivo therapeutic efficacy of ck2 inhibitor cx-4945 in acute myeloid leukemia', Cancers, vol. 13, no. 5, 1127, pp. 1-21. https://doi.org/10.3390/cancers13051127
Gvozdjan, K, Casey, H, Mowery, C, Kumer, L, Fisher, C, Tyler, J, Bayerl, MG, Malysz, J, Naik, S, Rybka, W, Ehmann, C, Claxton, D, Mineishi, S, Baker, M, Hong, Z & Shike, H 2021, 'Unexpected Short-Tandem-Repeat Patterns in Post-Transplant Chimerism Testing: Investigation of 3 Cases with Help from Forensic Science', Laboratory Medicine, vol. 51, no. 6, pp. 635-641. https://doi.org/10.1093/LABMED/LMAA022

2020

Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50. https://doi.org/10.1002/ajh.26043
Yan, B, Claxton, D, Huang, S & Qiu, Y 2020, 'AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy', Experimental Hematology, vol. 87, pp. 13-19. https://doi.org/10.1016/j.exphem.2020.06.003
Pearson, JM, Tan, SF, Sharma, A, Annageldiyev, C, Fox, TE, Abad, JL, Fabrias, G, Desai, D, Amin, S, Wang, HG, Cabot, MC, Claxton, DF, Kester, M, Feith, DJ & Loughran, TP 2020, 'Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia', Molecular Cancer Research, vol. 18, no. 3, pp. 352-363. https://doi.org/10.1158/1541-7786.MCR-19-0619
Gebru, MT, Atkinson, JM, Young, MM, Zhang, L, Tang, Z, Liu, Z, Lu, P, Dower, CM, Chen, L, Annageldiyev, C, Sharma, A, Kawasawa, YI, Zhao, Z, Miller, BA, Claxton, DF & Wang, HG 2020, 'Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia', Blood, vol. 136, no. 9, pp. 1067-1079. https://doi.org/10.1182/blood.2019003124
Pagel, JM, Othus, M, Garcia-Manero, G, Fang, M, Radich, JP, Rizzieri, DA, Marcucci, G, Strickland, SA, Litzow, MR, Lynn Savoie, M, Spellman, SR, Confer, DL, Chell, JW, Brown, M, Medeiros, BC, Sekeres, MA, Lin, TL, Uy, GL, Powell, BL, Bayer, RL, Larson, RA, Stone, RM, Claxton, D, Essell, J, Luger, SM, Mohan, SR, Moseley, A, Erba, HP & Appelbaum, FR 2020, 'Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients with Acute Myeloid Leukemia', JCO Oncology Practice, vol. 16, no. 6, pp. E464-E475. https://doi.org/10.1200/JOP.19.00133
Annageldiyev, C, Tan, SF, Thakur, S, Dhanyamraju, PK, Ramisetti, SR, Bhadauria, P, Schick, J, Zeng, Z, Sharma, V, Dunton, W, Dovat, S, Desai, D, Zheng, H, Feith, DJ, Loughran, TP, Amin, S, Sharma, AK, Claxton, D & Sharma, A 2020, 'The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia', Frontiers in Oncology, vol. 10, 393. https://doi.org/10.3389/fonc.2020.00393
Annageldiyev, C, Gowda, K, Patel, T, Bhattacharya, P, Tan, SF, Iyer, S, Desai, D, Dovat, S, Feith, DJ, Loughran, TP, Amin, S, Claxton, D & Sharma, A 2020, 'The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia', Haematologica, vol. 105, no. 3, pp. 687-696. https://doi.org/10.3324/haematol.2018.212886

2019

Stock, W, Luger, SM, Advani, AS, Yin, J, Harvey, RC, Mullighan, CG, Willman, CL, Fulton, N, Laumann, KM, Malnassy, G, Paietta, E, Parker, E, Geyer, S, Mrózek, K, Bloomfield, CD, Sanford, B, Marcucci, G, Liedtke, M, Claxton, DF, Foster, MC, Bogart, JA, Grecula, JC, Appelbaum, FR, Erba, H, Litzow, MR, Tallman, MS, Stone, RM & Larson, RA 2019, 'A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403', Blood, vol. 133, no. 14, pp. 1548-1559. https://doi.org/10.1182/blood-2018-10-881961
Tan, SF, Dunton, W, Liu, X, Fox, TE, Morad, SAF, Desai, D, Doi, K, Conaway, MR, Amin, S, Claxton, DF, Wang, HG, Kester, M, Cabot, MC, Feith, DJ & Loughran, TP 2019, 'Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation', Journal of Lipid Research, vol. 60, no. 6, pp. 1078-1086. https://doi.org/10.1194/jlr.M091876
Patel, TN, Madhunapantula, SRV, Annageldiyev, C, Claxton, D & Sharma, A 2019, Animal mouse models of acute myeloid leukemia. in A Azmi & RM Mohammad (eds), Animal Models in Cancer Drug Discovery. Academic Press, pp. 419-438. <https://www.sciencedirect.com/book/9780128147047/animal-models-in-cancer-drug-discovery>
Kao, LP, Morad, SAF, Davis, TS, MacDougall, MR, Kassai, M, Abdelmageed, N, Fox, TE, Kester, M, Loughran, TP, Abad, JL, Fabrias, G, Tan, SF, Feith, DJ, Claxton, DF, Spiegel, S, Fisher-Wellman, KH & Cabot, MC 2019, 'Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells', Journal of Lipid Research, vol. 60, no. 9, pp. 1590-1602. https://doi.org/10.1194/jlr.RA119000251
Kong, Y, Jia, B, Zhao, C, Claxton, DF, Sharma, A, Annageldiyev, C, Fotos, JS, Zeng, H, Paulson, RF, Prabhu, KS & Zheng, H 2019, 'Downregulation of CD73 associates with T cell exhaustion in AML patients', Journal of Hematology and Oncology, vol. 12, no. 1, 40. https://doi.org/10.1186/s13045-019-0728-3
Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Pu, JJ, Poulose, J, Malysz, J, Zhu, J, Fanburg-Smith, JC, Claxton, DF & Bayerl, MG 2019, 'Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study', British Journal of Haematology, vol. 186, no. 5, pp. e130-e133. https://doi.org/10.1111/bjh.15967
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684. https://doi.org/10.1111/bjh.16228
Kempin, S, Sun, Z, Kay, NE, Paietta, EM, Mazza, JJ, Ketterling, RP, Frankfurt, O, Claxton, DF, Saltzman, JN, Srkalovic, G, Callander, NS, Gross, G & Tallman, MS 2019, 'Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)', Acta Haematologica, vol. 142, no. 4, pp. 224-232. https://doi.org/10.1159/000500164
Spurgeon, SE, Sharma, K, Claxton, DF, Ehmann, C, Pu, J, Shimko, S, Stewart, A, Subbiah, N, Palmbach, G, LeBlanc, F, Latour, E, Chen, YY, Mori, M, Hasanali, Z & Epner, EM 2019, 'Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma', British Journal of Haematology, vol. 186, no. 6, pp. 845-854. https://doi.org/10.1111/bjh.16008
Barth, BM, Wang, W, Toran, PT, Fox, TE, Annageldiyev, C, Ondrasik, RM, Keasey, NR, Brown, TJ, Devine, VG, Sullivan, EC, Cote, AL, Papakotsi, V, Tan, SF, Shanmugavelandy, SS, Deering, TG, Needle, DB, Stern, ST, Zhu, J, Liao, J, Viny, AD, Feith, DJ, Levine, RL, Wang, HG, Loughran, TP, Sharma, A, Kester, M & Claxton, DF 2019, 'Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia', Blood Advances, vol. 3, no. 17, pp. 2598-2603. https://doi.org/10.1182/bloodadvances.2018021295
Cioccio, J & Claxton, D 2019, 'Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases', Expert Opinion on Investigational Drugs, vol. 28, no. 4, pp. 337-349. https://doi.org/10.1080/13543784.2019.1584610

2018

Jia, B, Wang, L, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, TD, Hohl, RJ & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Van De Louw, A, Desai, RJ, Zhu, J & Claxton, D 2018, 'Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia', Leukemia and Lymphoma, vol. 59, no. 10, pp. 2369-2376. https://doi.org/10.1080/10428194.2018.1435874
Rakszawski, K, Miki, K, Claxton, D, Wagner Jr., H, Shike, H, Mineishi, S & Naik, S 2018, 'Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML', International journal of hematology, vol. 108, no. 3, pp. 348-350. https://doi.org/10.1007/s12185-018-2431-5
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, DF, Helm, KF, Drabick, JJ, Robertson, GP, Neighbors, JD, Hohl, RJ & Schell, TD 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614. https://doi.org/10.1080/2162402X.2018.1539614
Prabhu, VV, Talekar, MK, Lulla, AR, Kline, CLB, Zhou, L, Hall, J, Van den Heuvel, APJ, Dicker, DT, Babar, J, Grupp, SA, Garnett, MJ, McDermott, U, Benes, CH, Pu, JJ, Claxton, DF, Khan, N, Oster, W, Allen, JE & El-Deiry, WS 2018, 'Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies', Cell Cycle, vol. 17, no. 4, pp. 468-478. https://doi.org/10.1080/15384101.2017.1403689
McGill, CM, Tomco, PL, Ondrasik, RM, Belknap, KC, Dwyer, GK, Quinlan, DJ, Kircher, TA, Andam, CP, Brown, TJ, Claxton, DF & Barth, BM 2018, 'Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia', Phytotherapy Research, vol. 32, no. 8, pp. 1636-1641. https://doi.org/10.1002/ptr.6091
Mato, AR, Nabhan, C, Thompson, MC, Lamanna, N, Brander, DM, Hill, B, Howlett, C, Skarbnik, A, Cheson, BD, Zent, C, Pu, J, Kiselev, P, Goy, A, Claxton, D, Isaac, K, Kennard, KH, Timlin, C, Landsburg, D, Winter, A, Nasta, SD, Bachow, SH, Schuster, SJ, Dorsey, C, Svoboda, J, Barr, P & Ujjani, CS 2018, 'Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: A real-world analysis', Haematologica, vol. 103, no. 5, pp. 874-879. https://doi.org/10.3324/haematol.2017.182907
Wang, L, Jia, B, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, RJ & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Zhu, L, Kong, Y, Zhang, J, Claxton, DF, Ehmann, WC, Rybka, WB, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, TD, Hohl, RJ, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Salzberg, AC, Harris-Becker, A, Popova, EY, Keasey, N, Loughran, TP, Claxton, DF & Grigoryev, SA 2017, 'Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability', PloS one, vol. 12, no. 3, e0173723. https://doi.org/10.1371/journal.pone.0173723
Schneider, C, Bayerl, M, Boyer, C, Desai, R, Claxton, D & Van De Louw, A 2017, 'Increased CD13 expression in acute myeloid leukemia-associated early acute hypoxic respiratory failure', American journal of respiratory and critical care medicine, vol. 196, no. 8, pp. 1077-1080. https://doi.org/10.1164/rccm.201701-0080LE
Goldenberg, D, Joshi, M, Malysz, J, Claxton, D & Cottrill, EE 2017, 'Myeloid sarcoma of the thyroid', Ear, Nose and Throat Journal, vol. 96, no. 12, pp. 460-461. https://doi.org/10.1177/014556131709601205
Mato, AR, Hill, BT, Lamanna, N, Barr, PM, Ujjani, CS, Brander, DM, Howlett, C, Skarbnik, AP, Cheson, BD, Zent, CS, Pu, JJ, Kiselev, P, Foon, K, Lenhart, J, Henick Bachow, S, Winter, AM, Cruz, AL, Claxton, DF, Goy, A, Daniel, C, Isaac, K, Kennard, KH, Timlin, C, Fanning, M, Gashonia, L, Yacur, M, Svoboda, J, Schuster, SJ & Nabhan, C 2017, 'Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, no. 5, pp. 1050-1056. https://doi.org/10.1093/annonc/mdx031
Abendroth, MD, Bayerl, MG, Wilkinson, MJ, Claxton, DF & Specht, CS 2017, 'Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman', Ocular Oncology and Pathology, vol. 4, no. 1, pp. 61-65. https://doi.org/10.1159/000478747
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Kawasawa, YI, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, DF, Rybka, WB, Drabick, JJ, Wang, HG, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, JJ 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features', Oncotarget, vol. 8, no. 18, pp. 29887-29905. https://doi.org/10.18632/oncotarget.15136
Hengst, J, Dick, TE, Sharma, A, Doi, K, Hegde, S, Tan, SF, Geffert, L, Fox, TE, Sharma, AK, Desai, D, Amin, S, Kester, M, Loughran, TP, Paulson, R, Claxton, D, Wang, H-G & Yun, J 2017, 'SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models', Cancer Translational Medicine, vol. 3, no. 4, pp. 109-121. <http://www.cancertm.com/article.asp?issn=2395-3977;year=2017;volume=3;issue=4;spage=109;epage=121;aulast=Hengst;type=0>
Doshi, UA, Shaw, J, Fox, TE, Claxton, DF, Loughran, TP & Kester, M 2017, 'STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia', Signal Transduction and Targeted Therapy, vol. 2, e17051. https://doi.org/10.1038/sigtrans.2017.51
Perl, AE, Altman, JK, Cortes, J, Smith, C, Litzow, M, Baer, MR, Claxton, D, Erba, HP, Gill, S, Goldberg, S, Jurcic, JG, Larson, RA, Liu, C, Ritchie, E, Schiller, G, Spira, AI, Strickland, SA, Tibes, R, Ustun, C, Wang, ES, Stuart, R, Röllig, C, Neubauer, A, Martinelli, G, Bahceci, E & Levis, M 2017, 'Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study', The Lancet Oncology, vol. 18, no. 8, pp. 1061-1075. https://doi.org/10.1016/S1470-2045(17)30416-3
Levy, MA & Claxton, D 2017, 'Therapeutic inhibition of BCL-2 and related family members', Expert Opinion on Investigational Drugs, vol. 26, no. 3, pp. 293-301. https://doi.org/10.1080/13543784.2017.1290078

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)